C93.12 Chronic myelomonocytic leukemia, in relapse

Name of the Condition

• Chronic myelomonocytic leukemia, in relapse
• ICD-10 Code: C93.12

Summary

Chronic myelomonocytic leukemia in relapse (CMML-R) is a myelodysplastic/myeloproliferative neoplasm where disease activity has returned after a period of remission. This state is defined by the reappearance of active disease manifestations, such as cytopenias or organ infiltration, following prior therapeutic response. Relapse indicates that underlying genetic abnormalities may persist and require renewed intervention. Remission does not imply cure, as the condition may recur.

Causes

The development involves genetic mutations in hematopoietic stem cells, often including TET2, ASXL1, SRSF2, or RUNX1. These mutations drive uncontrolled proliferation and impaired differentiation of myeloid precursors. Secondary cases may arise from prior chemotherapy, radiation, or myelodysplastic syndromes, though de novo occurrences are more common.

Risk Factors

• Prior exposure to chemotherapy or radiation therapy
• Myelodysplastic syndromes or myeloproliferative neoplasms
• Advanced age (peak incidence in older adults)
• Male gender (slightly higher prevalence)
• Environmental exposures (e.g., benzene)

Symptoms

• Persistent fatigue or weakness
• Unexplained fever or night sweats
• Frequent infections
• Easy bruising or bleeding
• Bone or joint pain
• Abdominal discomfort due to organ infiltration
• Weight loss

Diagnosis

Diagnosis requires confirmation of relapse through clinical and laboratory evaluation. Key steps include: (1) Review of prior treatment history and remission status; (2) Blood tests showing recurrent monocytosis (≥1×10⁹/L) and cytopenias; (3) Bone marrow biopsy demonstrating dysplasia in myeloid lineages and increased monocyte precursors; (4) Cytogenetic or molecular testing to identify persistent or new mutations. Imaging may be used to assess organ involvement.

Treatment Options

Treatment focuses on managing relapse and may include: (1) Reintroduction of prior effective therapies (e.g., hypomethylating agents); (2) Allogeneic stem cell transplantation for eligible patients; (3) Supportive care (e.g., blood transfusions, infection management); (4) Clinical trial enrollment for novel agents. Decisions depend on patient age, comorbidities, and prior response.

Prognosis and Follow-Up

Prognosis varies based on disease biology and treatment response. Relapse may shorten survival compared to initial diagnosis. Regular monitoring (e.g., blood counts, bone marrow assessments) is essential to detect further progression. Follow-up intervals are tailored to risk stratification and treatment tolerance.

Complications

• Cytopenias leading to infection, bleeding, or fatigue
• Organ infiltration (e.g., splenomegaly, hepatomegaly)
• Transformation to acute myeloid leukemia
• Treatment-related toxicities (e.g., myelosuppression)

Lifestyle & Prevention

No specific lifestyle changes prevent relapse, but general health maintenance supports quality of life. This includes balanced nutrition, infection prevention (e.g., vaccinations), and avoiding known environmental toxins. Patients should adhere to prescribed therapies and attend follow-up appointments.

When to Seek Professional Help

Seek care if symptoms recur or worsen, such as persistent fever, unexplained bleeding, or severe fatigue. Prompt evaluation is critical to confirm relapse and adjust treatment. Contact a hematologist or oncologist for any concerning changes.

Tips for Medical Coders

Code C93.12 is used when chronic myelomonocytic leukemia is documented as in relapse. Ensure documentation specifies "relapse" or equivalent terminology (e.g., "recurrence," "return of disease"). Do not use this code for active disease without prior remission or for remission states. Verify that the diagnosis aligns with clinical findings and treatment history.